Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of ...

March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the Lexington ...

VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...

S&P 500 E-Mini futures (ESH25) are up +0.41%, andMarch Nasdaq 100 E-Mini futures (NQH25) are up +0.53% this morning, pointing ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Explore the detailed Voyager Therapeutics Inc balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total ...